Predictors of hepatic steatosis in HBeAG-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis

International Journal of Medical Sciences

Volumn 7, Issue 5, 2010, Pages 272-277

  Zheng, Rui Dan ^a   Xu, Cheng Run ^a   Jiang, Li ^a   Dou, Ai Xia ^b   Zhou, Kun ^b   Lu, Lun Gen ^b  

^a Southeast Hospital   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chronic hepatitis B; HBeAG negative; Liver biopsy; Nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLOBULIN; GLUCOSE; HEPATITIS B(E) ANTIGEN; INSULIN; TRIACYLGLYCEROL; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; GLUCOSE BLOOD LEVEL; HEPATITIS B; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER FIBROSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77956958856     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.7.272     Document Type: Article

References (15)

1. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis. 2006; 26:130-41.
2. Bondini S, Kallman J, Wheeler A, et al. Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int. 2007;27:607-11.
3. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-95.
4. Angulo P. Nonalcoholic fatty liver disease. Rev Gastroenterol Mex. 2005; 70:52-6.
5. Bondini S, Younossi ZM. Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Gastroenterol Dietol. 2006; 52:135-43.
6. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45:507-39.
7. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and bcell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412-9.
8. Farrell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007; 22: 775-7.
9. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc. 2007; 82:967-75.
10. Keeffe EB, Marcellin P. New and emerging treatment of chronic hepatitis B. Clin Gastroenterol Hepatol. 2007; 5:285-94.
11. Persico M, Iolascon A. Steatosis as a co-factor in chronic liver diseases. World J Gastroenterol. 2010;16:1171-6.
12. Bondini S, Kallman J, Wheeler A, et al. Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int. 2007; 27:607-611.
13. Gordon A, McLean CA, Pedersen JS, et al. Hepatic steatosis in chronic hepatitis B and C: Predictors, distribution and effect on fibrosis. J Hepatol. 2005; 43:38-44.
14. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44:865-73.
15. Demir K, Akyuz F, Ozdil S. What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis? Ann Hepatol. 2007; 6:92-6.